"Real-world" eligibility for aducanumab depends on clinical setting and patients' journey

J Am Geriatr Soc. 2022 Feb;70(2):626-628. doi: 10.1111/jgs.17530. Epub 2021 Nov 9.

Authors

Alessandro Padovani^{1

2}, Salvatore Caratozzolo², Luca Rozzini^{1

2}, Andrea Pilotto^{1

2}, Alberto Benussi^{1

2}, Gioacchino Tedeschi³

Affiliations

¹ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
² Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy.
³ Neurology Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Abstract

See related editorial by Lundebjerg et al.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Alzheimer Disease / drug therapy*
Antibodies, Monoclonal, Humanized / therapeutic use*
Cognitive Dysfunction / drug therapy*
Disease Progression*
Drug Approval
Eligibility Determination*
Humans
United States
United States Food and Drug Administration

Substances

Antibodies, Monoclonal, Humanized
aducanumab